Ignite Creation Date:
2025-12-24 @ 6:56 PM
Ignite Modification Date:
2026-01-02 @ 8:17 AM
Study NCT ID:
NCT02060357
Status:
COMPLETED
Last Update Posted:
2015-08-07
First Post:
2014-01-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)
Sponsor:
Barts & The London NHS Trust
Organization:
Study Overview
Official Title:
Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes
Status:
COMPLETED
Status Verified Date:
2015-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OCT-DES
Brief Summary:
The aim of this study is a comparative evaluation of re-endothelailisation of the Integrity Resolute zotarolimus eluting stent (Medtronic) and of the Promus Element erolimus eluting stent (Boston Scientific), in patients with diabetes.
We plan to compare endothelial coverage and neointimal proliferation using OCT and compare this data to published results from conventional stents.
We plan to compare endothelial coverage and neointimal proliferation using OCT and compare this data to published results from conventional stents.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: